Key result
Cardiomyocyte-restricted deletion of cGKI in mice provoked dilated cardiomyopathy and marked deterioration of cardiac function following pathological stimulation with angiotensin II or transverse aortic constriction.
Why the study?
Does cardiomyocyte-restricted inactivation of cGKI alter cardiac hypertrophic and contractile responses to pathological stimulation in mice?
Does cardiomyocyte-restricted inactivation of cGKI alter cardiac hypertrophic and contractile responses to pathological stimulation in mice?
Loss of cGKI in cardiac myocytes compromises the hypertrophic program to pathological stimulation, rendering the heart more susceptible to dysfunction and dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Cardiomyocyte cGKI loss heightens stress-induced cardiomyopathy risk in mice; hypothesis-generating for cGKI-targeted therapies in human HF.
AIMS: Cardiac hypertrophy is a common and often lethal complication of arterial hypertension. Elevation of myocyte cyclic GMP levels by local actions of endogenous atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) or by pharmacological inhibition of phosphodiesterase-5 was shown to counter-regulate pathological hypertrophy. It was suggested that cGMP-dependent protein kinase I (cGKI) mediates this protective effect, although the role in vivo is under debate. Here, we investigated whether cGKI modulates myocyte growth and/or function in the intact organism. METHODS AND RESULTS: To circumvent the systemic phenotype associated with germline ablation of cGKI, we inactivated the murine cGKI gene selectively in cardiomyocytes by Cre/loxP-mediated recombination. Mice with cardiomyocyte-restricted cGKI deletion exhibited unaltered cardiac morphology and function under resting conditions. Also, cardiac hypertrophic and contractile responses to β-adrenoreceptor stimulation by isoprenaline (at 40 mg/kg/day during 1 week) were unaltered. However, angiotensin II (Ang II, at 1000 ng/kg/min for 2 weeks) or transverse aortic constriction (for 3 weeks) provoked dilated cardiomyopathy with marked deterioration of cardiac function. This was accompanied by diminished expression of the [Ca(2+)]i-regulating proteins SERCA2a and phospholamban (PLB) and a reduction in PLB phosphorylation at Ser16, the specific target site for cGKI, resulting in altered myocyte Ca(2+)i homeostasis. In isolated adult myocytes, CNP, but not ANP, stimulated PLB phosphorylation, Ca(2+)i-handling, and contractility via cGKI. CONCLUSION: These results indicate that the loss of cGKI in cardiac myocytes compromises the hypertrophic program to pathological stimulation, rendering the heart more susceptible to dysfunction. In particular, cGKI mediates stimulatory effects of CNP on myocyte Ca(2+)i handling and contractility.
No takes yet. Share an insight, caveat, or question.
Frantz et al. (2011) studied Cardiac hypertrophy and dilated cardiomyopathy. Cardiomyocyte-restricted cGKI deletion vs. Wild-type/control mice (implied) was evaluated on Cardiac hypertrophic and contractile responses to pathological stimulation. Cardiomyocyte-restricted deletion of cGKI in mice provoked dilated cardiomyopathy and marked deterioration of cardiac function following pathological stimulation with angiotensin II or transverse aortic constriction.
Synapse has enriched 10 related papers. Consider them for comparative context: